Aldesleukin (ILTOO Pharma)

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameAldesleukin (ILTOO Pharma)
Drug Alias NameLow dose il2Low dose IL-2Low dose rhIL2ILT-101
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonistsRegulatory T-lymphocytes stimulants
TargetsInterleukin-2 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Autism Spectrum DisorderBipolar Disorder +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaRomaniaPortugal +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAssistance Publique Hopitaux De ParisInserm
China Registration ClassN/A

Develop Information

Active CompaniesAssistance Publique Hopitaux De Paris
Inactive CompaniesIltoo Pharma
Active IndicationsAutism Spectrum DisorderBipolar DisorderDiabetes Mellitus, Type 1 +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Lupus Erythematosus, SystemicMultiple Sclerosis, Relapsing-Remitting +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG